Coordinate hyperactivation of notch1 and Ras/MAPK pathways correlates with poor patient survival: Novel therapeutic strategy for aggressive breast cancers

Molecular Cancer Therapeutics

Volumn 13, Issue 12, 2014, Pages 3198-3209

  Mittal, Suruchi ^a,b   Sharma, Ankur ^a   Balaji, Sai A ^a   Gowda, Manju C ^b   Dighe, Rajan R ^a   Kumar, Rekha V ^b   Rangarajan, Annapoorni ^a  

^a INDIAN INSTITUTE OF SCIENCE   (India)

^b KIDWAI MEMORIAL INSTITUTE OF ONCOLOGY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; MITOGEN ACTIVATED PROTEIN KINASE; NOTCH1 RECEPTOR; RAS PROTEIN; ANTINEOPLASTIC AGENT; CD24 ANTIGEN; HERMES ANTIGEN; PROTEIN KINASE INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER SURVIVAL; CELL POPULATION; CELL PROLIFERATION; CHILD; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; NONHUMAN; OUTCOME ASSESSMENT; OVERALL SURVIVAL; RELAPSE; SCHOOL CHILD; STEM CELL; TRIPLE NEGATIVE BREAST CANCER; TUMOR GROWTH; TUMOR INVASION; XENOGRAFT; ANIMAL; BREAST NEOPLASMS; CELL SURVIVAL; DISEASE COURSE; DISEASE MODEL; DRUG EFFECTS; DRUG SCREENING; FOLLOW UP; IMMUNOPHENOTYPING; LYMPH NODE METASTASIS; METABOLISM; MORTALITY; MOUSE; MULTICELLULAR SPHEROID; PATHOLOGY; PROGNOSIS; SIGNAL TRANSDUCTION; TUMOR CELL CULTURE; TUMOR CELL LINE; TUMOR RECURRENCE;

ANIMALS; ANTIGENS, CD24; ANTIGENS, CD44; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOPHENOTYPING; LYMPHATIC METASTASIS; MICE; MITOGEN-ACTIVATED PROTEIN KINASES; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; PROTEIN KINASE INHIBITORS; RAS PROTEINS; RECEPTOR, NOTCH1; SIGNAL TRANSDUCTION; SPHEROIDS, CELLULAR; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84917709274     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-14-0280     Document Type: Article

References (47)

1. Shetty P. India faces growing breast cancer epidemic. J Lancet 2012;379:992-3.
2. Graham LJ, Shupe MP, Schneble EJ, Flynt FL, Clemenshaw MN, Kirkpatrick AD, et al. Current approaches and challenges in monitoring treatment responses in breast cancer. J Cancer 2014;5:58-68.
3. Blows FM, Driver KE, Schmidt MK, Broeks A, van Leeuwen FE, Wesseling J, et al. Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and longterm survival: a collaborative analysis of data for 10,159 cases from 12 studies. PLoS Med 2010;7:e1000279.
4. Di Cosimo S, Baselga J. Management of breast cancer with targeted agents: importance of heterogeneity. [corrected]. Nat Rev Clin Oncol 2010;7:139-47.
5. Arnedos M, Bihan C, Delaloge S, Andre F. Triple-negative breast cancer: are we making headway at least? Ther Adv Med Oncol 2012;4:195-210.
6. Artavanis-Tsakonas S, Muskavitch MA. Chapter one-notch: the past, the present, and the future. Curr Top Dev Biol 2010;92:1-29.
7. Kopan R, Ilagan MXG. The canonical Notch signaling pathway: unfolding the activation mechanism. Cell 2009;137:216-33.
8. Ranganathan P, Weaver KL, Capobianco AJ. Notch signalling in solid tumours: a little bit of everything but not all the time. Nat Rev Can 2011;11:338-51.
9. Stylianou S, Clarke RB, Brennan K. Aberrant activation of notch signaling in human breast cancer. Cancer Res 2006;66:1517-25.
10. Reedijk M, Odorcic S, Chang L, Zhang H, Miller N, McCready DR, et al. High-level coexpression of JAG1 and NOTCH1 is observed in human breast cancer and is associated with poor overall survival. Cancer Res 2005;65:8530-7.
11. Mittal S, Subramanyam D, Dey D, Kumar RV, Rangarajan A. Cooperation of Notch and Ras/MAPK signaling pathways in human breast carcinogenesis. Mol Cancer 2009;8:128.
12. Speiser J, Foreman K, Drinka E, Godellas C, Perez C, Salhadar A, et al. Notch-1 and Notch-4 biomarker expression in triple-negative breast cancer. Int J Surg Pathol 2012;20:139-45.
13. Clementz AG, Rogowski A, Pandya K, Miele L, Osipo C. NOTCH-1 and NOTCH-4 are novel gene targets of PEA3 in breast cancer: novel therapeutic implications. Breast Cancer Res 2011;13:R63.
14. Dontu G, Jackson KW, McNicholas E, Kawamura MJ, Abdallah WM, Wicha MS. Role of Notch signaling in cell-fate determination of human mammary stem/progenitor cells. Breast Cancer Res 2004;6:R605-R15.
15. Sharma A, Paranjape AN, Rangarajan A, Dighe RR. A monoclonal antibody against human Notch1 ligand-binding domain depletes subpopulation of putative breast cancer stem-like cells. Mol Cancer Ther 2012;11:77-86.
16. Al-Hussaini H, Subramanyam D, Reedijk M, Sridhar SS. Notch signaling pathway as a therapeutic target in breast cancer. Mol Cancer Ther 2011;10:9-15.
17. Rizzo P, Miao H, D'Souza G, Osipo C, Yun J, Zhao H, et al. Cross-talk between notch and the estrogen receptor in breast cancer suggests novel therapeutic approaches. Cancer Res 2008;68:5226-35.
18. Farnie G, Willan PM, Clarke RB, Bundred NJ. Combined inhibition of ErbB1/2 and Notch receptors effectively targets breast ductal carcinoma in situ (DCIS) stem/progenitor cell activity regardless of ErbB2 status. PloS ONE 2013;8:e56840.
19. Roberts P, Der C. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 2007;26:3291-310.
20. Weijzen S, Rizzo P, Braid M, Vaishnav R, Jonkheer SM, Zlobin A, et al. Activation of Notch-1 signaling maintains the neoplastic phenotype in human Ras-transformed cells. Nat Med 2002;8:979-86.
21. Fitzgerald K, Harrington A, Leder P. Ras pathway signals are required for notch-mediated oncogenesis. Oncogene 2000;19:4191-8.
22. Paranjape AN, Mandal T, Mukherjee G, Kumar MV, Sengupta K, Rangarajan A. Introduction of SV40ER and hTERT into mammospheres generates breast cancer cells with stem cell properties. Oncogene 2012;31:1896-909.
23. Dey D, Saxena M, Paranjape AN, Krishnan V, Giraddi R, Kumar MV, et al. Phenotypic and functional characterization of human mammary stem/progenitor cells in long-term culture. PLoS ONE 2009;4:e5329.
24. Muchir A, Shan J, Bonne G, Lehnart SE, Worman HJ. Inhibition of extracellular signal-regulated kinase signaling to prevent cardiomyopathy caused by mutation in the gene encoding A-type lamins. Hum Mol Genet 2009;18:241-7.
25. Cavalli LR. Molecular markers of breast axillary lymph node metastasis. Expert Rev Mol Diagn 2009;9:441-54.
26. Michaelson JS, Silverstein M, Sgroi D, Cheongsiatmoy JA, Taghian A, Powell S, et al. The effect of tumor size and lymph node status on breast carcinoma lethality. Cancer 2003;98:2133-43.
27. Andersson ER, Lendahl U. Therapeutic modulation of Notch signalling - are we there yet? Nat Rev Drug Discov 2014;13:357-78.
28. Santarpia L, Lippman SM, El-Naggar AK. Targeting the MAPK-RAS-RAF signaling pathway in cancer therapy. Expert Opin Ther Targets 2012;16:103-19.
29. Jorissen E, DeStrooper B. Chapter six-γ-secretase and the intramembrane proteolysis of Notch. Curr Top Dev Biol 2010;92:201-30.
30. van Es JH, van Gijn ME, Riccio O, van den Born M, Vooijs M, Begthel H, et al. Notch/γ-secretase inhibition turns proliferative cells in intestinal crypts and adenomas into goblet cells. Nature 2005;435:959-63.
31. Wu Y, Cain-Hom C, Choy L, Hagenbeek TJ, de Leon GP, Chen Y, et al. Therapeutic antibody targeting of individual Notch receptors. Nature 2010;464:1052-7.
32. Yao J, Qian C, Shu T, Zhang X, Zhao Z, Liang Y. Combination treatment of PD98059 and DAPT in gastric cancer through induction of apoptosis and downregulation of WNT/β-catenin. Cancer Biol Ther 2013;14:833-9.
33. Izrailit J, Berman HK, Datti A, Wrana JL, Reedijk M. High-throughput kinase inhibitor screens reveal TRB3 and MAPK-ERK/TGFβ pathways as fundamental Notch regulators in breast cancer. Proc Natl Acad Sci U S A 2013;110:1714-9.
34. Clevers H. The cancer stem cell: premises, promises, and challenges. Nat Med 2011:313-9.
35. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A 2003;100:3983-8.
36. Buyse M, Loi S, Van'tVeer L, Viale G, Delorenzi M, Glas AM, et al. Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J Natl Cancer Inst 2006;98:1183-92.
37. Sotiriou C, Pusztai L. Gene-expression signatures in breast cancer. N Engl J Med 2009;360:790-800.
38. Rizzo P, Osipo C, Foreman K, Golde T, Osborne B, Miele L. Rational targeting of Notch signaling in cancer. Oncogene 2008;27:5124-31.
39. Clark GJ, Der CJ. Aberrant function of the Ras signal transduction pathway in human breast cancer. Breast Cancer Res Treat 1995;35:133-44.
40. Zelivianski S, Spellman M, Kellerman M, Kakitelashvilli V, Zhou XW, Lugo E, et al. ERK inhibitor PD98059 enhances docetaxel-induced apoptosis of androgen-independent human prostate cancer cells. Int J Cancer 2003;107:478-85.
41. Leverentz MK, Acar A, Brennan K. Notch: evidence for combining therapies to treat breast cancer. Breast Cancer Management 2013;2:481-8.
42. Liu X, Johnson S, Liu S, Kanojia D, Yue W, Singh UP, et al. Nonlinear growth kinetics of breast cancer stem cells: implications for cancer stem cell targeted therapy. Sci Rep 2013;3:2473.
43. Nahta R, Yu D, Hung M-C, Hortobagyi GN, Esteva FJ. Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer. Nat Clin Pract Oncol 2006;3:269-80.
44. Duffy MJ, McGowan PM, Crown J. Targeted therapy for triple-negative breast cancer: where are we? Int J Cancer 2012;131:2471-7.
45. Zhang S, Chung W-c, Miele L, Xu K. Targeting Met and Notch in the Lfng-de ficient, Met-amplified triple negative breast cancer. Cancer Biol Ther 2014;15:633-42.
46. Espinoza I, Miele L. Notch inhibitors for cancer treatment. Pharmacol Ther 2013;139:95-110.
47. Santarpia L, Lippman SM, El-Naggar AK. Targeting the MAPK-RAS-RAF signaling pathway in cancer therapy. Expert Opin Ther Targets 2012;16:103-19.